Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
Cohort Analysis
43%
Overall Survival
35%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
32%
International Prognostic Index
25%
Non-Hodgkin Lymphoma
22%
B Cell
18%
Large-Cell Lymphoma
18%
Malignant Neoplasm
14%
Infection
14%
CHOP
12%
Chemotherapy
12%
Rituximab
11%
Disease
11%
Follicular Lymphoma
11%
Hazard Ratio
11%
Comorbidity
10%
Central Nervous System
10%
Hodgkin's Lymphoma
10%
CD20
9%
Progression Free Survival
9%
Prognostic Factor
8%
Neutropenia
8%
T Cell
8%
Peripheral T-Cell Lymphoma
7%
Antineoplastic Activity
7%
Proportional Hazards Model
7%
Elderly Patient
7%
Positron Emission Tomography-Computed Tomography
6%
Anthracycline
6%
Clinical Trial
6%
Medical Record
6%
Doxorubicin
6%
Cancer
6%
Cytokine Release Syndrome
5%
Patient with Non-Hodgkins Lymphoma
5%
Drug Megadose
5%
B-Cell Chronic Lymphocytic Leukemia
5%
Bispecific Antibody
5%
Neoplasm
5%
Survival Rate
5%
Pharmacology, Toxicology and Pharmaceutical Science
Diffuse Large B Cell Lymphoma
65%
Overall Survival
24%
Cohort Study
24%
Large Cell Lymphoma
18%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
16%
Nonhodgkin Lymphoma
15%
Malignant Neoplasm
13%
Disease
13%
Chemotherapy
11%
Follicular Lymphoma
10%
Progression Free Survival
9%
SARS Coronavirus
9%
Rituximab
9%
Comorbidity
9%
Antitumor Activity
7%
Monotherapy
6%
Cytokine Release Syndrome
6%
Infection
6%
Polyethylene Terephthalate
6%
Anthracycline
6%
Bispecific Antibody
5%
Doxorubicin
5%
Adverse Event
5%
Immunology and Microbiology
B Cell
62%
Overall Survival
26%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
16%
T Cell
13%
Cytokine Release Syndrome
11%
Rituximab
10%
Lymphoma Cell
10%
Comorbidity
9%
CD20
9%
Drug Megadose
7%
Progression Free Survival
7%
Antineoplastic Activity
6%
Medical Record
5%
Arm
5%
Survival Rate
5%
Bispecific Antibody
5%
